Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Modified Delphi study of decision‐making around treatment sequencing in relapsing–remitting multiple sclerosis.

Tytuł:
Modified Delphi study of decision‐making around treatment sequencing in relapsing–remitting multiple sclerosis.
Autorzy:
Piena, M. A. (AUTHOR)
Schoeman, O. (AUTHOR)
Palace, J. (AUTHOR)
Duddy, M. (AUTHOR)
Harty, G. T. (AUTHOR)
Wong, S. L. (AUTHOR)
Temat:
MULTIPLE sclerosis
DELPHI method
MAGNETIC resonance imaging
KNOWLEDGE gap theory
DISEASE duration
Źródło:
European Journal of Neurology. Aug2020, Vol. 27 Issue 8, p1530-1536. 7p. 2 Diagrams, 1 Chart.
Czasopismo naukowe
Background and purpose: Existing effectiveness models of disease‐modifying drugs (DMDs) for relapsing–remitting multiple sclerosis (RRMS) evaluate a single line of treatment; however, RRMS patients often receive more than one lifetime DMD. To develop treatment sequencing models grounded in clinical reality, a detailed understanding of the decision‐making process regarding DMD switching is required. Using a modified Delphi approach, this study attempted to reach consensus on modelling assumptions. Methods: A modified Delphi technique was conducted based on three rounds of discussion amongst an international group of 10 physicians with expertise in RRMS. Results: The panel agreed that the expected time from disease onset to Expanded Disability Status Scale 6.0 is a proxy for disease severity as well as suitable for classifying severity into three groups. A modelled clinical decision rule regarding the timing of switching should contain at least the time between relapses, magnetic resonance imaging outcomes and the occurrence/risk of adverse events. The experts agreed that the assessment of adverse event risk for a DMD is dependent on disease severity, with more risks accepted when the patient's disease is more severe. The effectiveness of DMDs conditional on their position in a sequence and/or disease duration was discussed: there was consensus on some statements regarding this topic but these were accompanied by a high degree of uncertainty due to considerable knowledge gaps. Conclusion: Useful insights into the medical decision‐making process regarding treatment sequencing in RRMS were obtained. The knowledge gained has been used to validate the main modelling concepts and to further generate clinically meaningful results. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies